|Home | About | Journals | Submit | Contact Us | Français|
Conceived and designed the experiments: WD JB YZ ZX. Performed the experiments: WD YY HZ JB JW HY. Analyzed the data: WD YY HZ JB YZ ZX. Contributed reagents/materials/analysis tools: ZX. Wrote the paper: WD JB ZX.
The Murine Double Minute 2 (MDM2) protein is a key regulator of cell proliferation and apoptosis that acts primarily by inhibiting the p53 tumor suppressor. Similarly, the PI3-Kinase (PI3K)/AKT pathway is critical for growth factor-mediated cell survival. Additionally, it has been reported that AKT can directly phosphorylate and activate MDM2. In this study, we show that IGF-1 up-regulates MDM2 protein levels in a PI3K/AKT-dependent manner. Inhibition of mTOR by rapamycin or expression of a dominant negative eukaryotic initiation factor 4E binding protein 1 (4EBP1) mutant protein, as well as ablation of eukaryotic initiation factor 4E (eIF4E), efficiently abolishes IGF-1-mediated up-regulation of MDM2. In addition, we show that rapamycin effectively inhibits MDM2 expression and sensitizes cancer cells to chemotherapy. Taken together, this study reveals a novel mechanism by which IGF-1 activates MDM2 via the mTOR pathway, and that pharmacologic inhibition of mTOR combined with chemotherapy may be more effective in treatment of a subset of cancers harboring increased MDM2 activation.
Abnormal activation of Murine Double Minute 2 (MDM2) has been established as an important causative factor in human cancer development. MDM2 functions as an ubiquitin E3 ligase to facilitate degradation of p53, a key regulator for cell proliferation, apoptosis and senescence in response to cellular stresses, such as DNA damage and oncogenic stress . Amplification of the MDM2 gene has been observed in a variety of human tumors and cancers, including soft tissue tumors, osteosarcoma, and esophageal carcinoma . Notably, MDM2 has been shown to possess p53-independent oncogenic functions , . Work from us and others have shown that MDM2 can target and inhibit retinoblastoma protein (Rb) via proteasome-mediated degradation , , , , . MDM2 has also been shown to complex with and regulate protein stability and/or activity of a subset of proteins involved in cell proliferation and cell death, including p73 , , E2F1 , cyclin-dependent kinase inhibitor p21 , beta-arrestin, and G-protein-coupled receptor kinase 2 (GRK2) , .
It has been shown that MDM2 protein subcellular localization and functions are modulated by the PI3-Kinase (PI3K)/AKT pathway. AKT can directly phosphorylate MDM2 at Ser166 and Ser188, thus facilitating nuclear translocation  and p53 degradation, as well as p300 interaction , . In addition, overexpression of AKT has been shown to stabilize MDM2 protein . Recently, AKT has emerged as a critical regulator of mammalian target of rapamycin complex 1 (mTORC1). AKT inhibits the TSC2/TSC1 complex, leading to activation of mTORC1 . Importantly, emerging evidence suggests that mTORC1 activity is critical for AKT oncogenic function. Indeed, accelerated tumor growth upon constitutive activation of AKT is reversed by inhibition of mTOR . Similarly, mice expressing human AKT1 in the prostate develop a neoplastic phenotype, which is completely abolished by inhibition of mTOR . Moreover, inactivation of AKT leads to inhibition of cell proliferation, which is dependent on mTORC1 . These studies suggest that the AKT-mTOR pathway is crucial for tumor cell growth.
In this study, we show that insulin-like growth factor 1 (IGF-1) up-regulates MDM2 expression through the AKT-mTOR pathway. Inhibition of mTOR by rapamycin, expression of a dominant negative eukaryotic initiation factor 4E binding protein 1 (4EBP1) mutant or silencing of eukaryotic initiation factor 4E (eIF4E) efficiently abrogate IGF-1-mediated up-regulation of MDM2. In addition, we show that rapamycin effectively inhibits MDM2 expression and sensitizes cancer cells to chemotherapeutic drug-induced apoptosis.
We have previously shown that IGF-1 modulates the cyclin-dependent kinase inhibitor p21 to impact on cell survival upon genotoxic stress . Since IGF-1 is known to activate the PI3K/AKT pathway, we were interested in deciphering the role of PI3K/AKT in IGF-1-mediated cell survival. As shown in Figure 1A, IGF-1 treatment of serum-starved human osteosarcoma U2-OS cells (p53 wild type) clearly led to AKT activation, as shown by an increase in AKT phosphorylation. Notably, IGF-1 induced MDM2 protein expression, as shown by an increase of both MDM2 protein bands detected by an MDM2-specific antibody, SMP14, consistent with previous reports , , . This effect of IGF-1 on MDM2 was effectively blocked by treatment with LY294002, a selective PI3K inhibitor , but not by PD98059, an inhibitor of MAP kinase kinase (MEK), or by SB203580, a specific inhibitor of p38 stress-activated protein kinase . These data suggest that IGF-1 up-regulates MDM2 protein expression through the PI3K-AKT signaling cascade.
Since we have previously shown that IGF-1 can activate p53, and MDM2 is a direct downstream p53 target , we asked whether the effect of IGF-1 on the expression of MDM2 is dependent on p53. We treated p53-null human non-small cell lung carcinoma H1299 cells with IGF-1. IGF-1 was still able to induce MDM2 protein expression in H1299 cells in a dose-dependent manner (Figure 1B), indicating that IGF-1-mediated up-regulation of MDM2 is independent of p53.
Next, we investigated whether IGF-1 up-regulates MDM2 protein levels by increasing its protein stability. As expected, IGF-1 increased MDM2 protein expression (Figure 2A). However, IGF-1 treatment did not significantly alter MDM2 protein half-life, as determined by treatment with the protein biosynthesis inhibitor cycloheximide (Figure 2A and 2B) and by pulse-chase experiments (Figure 2C and 2D). We then examined whether IGF-1 induces MDM2 by increasing its mRNA levels. However, quantitative PCR (Q-PCR) analysis showed that MDM2 mRNA levels were not significantly affected by IGF-1 treatment (Figure 2E), indicating that IGF-1 does not affect steady-state mRNA levels.
AKT has been shown to be an important regulator of mTORC1 activity. Thus, we investigated whether the mTOR pathway plays a role in IGF-1-mediated up-regulation of MDM2. To this end, we serum-starved and then pretreated U2-OS cells with rapamycin, a selective inhibitor for mTOR , prior to IGF-1 treatment. As expected, rapamycin blocked phosphorylation of the ribosomal protein S6 (Figure 3A). Notably, rapamycin also blocked IGF-1-induced MDM2 up-regulation (Figure 3A). Similar results were observed in H1299 cells, in which rapamycin abrogated IGF-1-induced MDM2 up-regulation and phosphorylation of 4EBP1 (Figure 3B). Moreover, expression of constitutively active AKT (myristic-AKT) led to an increase of MDM2 protein levels, which was completely blocked in the presence of rapamycin (Figure 3C). Taken together, these data strongly support the notion that a rapamycin-sensitive pathway is critical for up-regulation of MDM2 via IGF-1/PI3K/AKT signaling.
Since Heregulin can activate AKT, we asked whether this ligand could up-regulate MDM2 in an mTOR-dependent manner. MCF-7 cells or H1299 cells were serum-starved prior to treatment with rapamycin, and then treated with heregulin-beta (HRG). As shown on Figure 4A, activation of AKT signaling by HRG effectively induced MDM2 protein expression, which was completely blocked by rapamycin in both MCF-7 and H1299 cells (Figure 4A and 4B). In addition, the PI3K inhibitor LY294002 effectively inhibited the effect of HRG on the up-regulation of MDM2 (Figure 4B), indicating that Heregulin-mediated up-regulation of MDM2 is dependent on PI3K. Together, these data indicate that a rapamycin-sensitive pathway is required for up-regulation of MDM2 by the IGF-1 or Heregulin signaling pathways.
We next determined whether eIF4E, a major downstream target of mTOR, is involved in IGF-1-mediated up-regulation of MDM2. Since mTOR phosphorylates 4EBP1, resulting in its dissociation from eIF4E and leading to the formation of the translation initiation complex , we used mutant 4EBP1-5A, which lacks the five Ser/Thr phosphorylation sites targeted by mTOR and thus acts as a dominant negative inhibitor by binding elF4E to prevent translation initiation . To this end, H1299 cells were transiently transfected with either wild type 4EBP1 or 4EBP1-5A, followed by serum starvation and IGF-1 treatment. As shown in Figure 5A, IGF-1 treatment led to a sharp increase in phosphorylation of AKT, S6 and 4EBP1, correlated with a marked increase in MDM2 expression. Notably, expression of wild-type 4EBP1 did not significantly alter the effect of IGF-1 on MDM2 expression, likely due to effective phosphorylation of 4EBP1 in H1299 cells. However, IGF-1-mediated MDM2 up-regulation was significantly inhibited by ectopic expression of 4EBP1-5A. Next, in order to investigate the role of eIF4E directly, we ablated endogenous eIF4E using small interfering RNA (siRNA) in U2-OS cells. While silencing eIF4E did not significantly affect basal MDM2 expression (Figure 5B), knockdown of eIF4E completely abrogated the effect of IGF-1 on increasing MDM2 levels, despite evident 4EBP1 phosphorylation (Figure 5C).
In addition to phosphorylating and inhibiting 4EBP1, mTOR phosphorylates and activates ribosomal protein S6 Kinase (S6K), which in turn phosphorylates and activates ribosomal protein S6 in order to enhance protein translation. Thus, we ablated S6K by siRNA in U2-OS cells. As shown in Figure 5D and 5E, we observed similar effects as eIF4E knockdown, indicating IGF-1-mediated MDM2 up-regulation requires mTOR signaling, which involves both the eIF4E and S6K pathways.
Since MDM2 is a key negative regulator of p53, which is essential for DNA damage-induced apoptosis, we investigated the effect of rapamycin on doxorubicin-induced apoptosis in p53-positive cancer cells. We chose MCF-7 breast cancer cells because they harbor a somatic mutation in the PIK3CA gene that confers a constitutively active AKT-mTOR pathway . MCF-7 cells were pretreated with rapamycin, followed by treatment with a low dose of doxorubicin. Cell viability was assessed by trypan blue exclusion assay and western blot analysis for cleavage of poly ADP-ribose polymerase (PARP), a biochemical marker for apoptosis. Under these conditions, neither rapamycin nor doxorubicin alone significantly induced apoptosis. However, in the presence of rapamycin, doxorubicin effectively induced cell death (Figure 6A). Notably, rapamycin completely blocked up-regulation of MDM2, but not of p53 (Figure 6B). Similar phenomena were observed in human osteosarcoma SJSA-1 cells, which harbor MDM2 amplification  (Figure 6C and 6D). Together, these data suggest that rapamycin suppresses MDM2 protein expression, resulting in sensitization of cancer cells to doxorubicin-induced cell death.
We next investigated whether down-regulation of MDM2 plays a causative role in sensitization of cells to doxorubicin by rapamycin treatment. We treated U2-OS cells with rapamycin and doxorubicin either in the presence or absence of ectopic expression of MDM2. As shown in Figure 7A, MDM2 expression dramatically reverted cleaved PARP levels, compared to cells expressing a vector control. Notably, MDM2 expression reduced p53 protein levels, as well as Ser15 phosphorylation on p53. Moreover, MDM2 expression effectively rescued cell death induced by rapamycin plus doxorubicin combination treatment (Figure 7B and 7C). These data indicate that inhibition of MDM2 up-regulation by rapamycin is largely responsible for sensitizing cells to chemotherapeutic treatment.
In this study, we demonstrated that IGF-1 up-regulates MDM2 protein levels via the mTOR pathway, thus adding another layer of fine regulation to the MDM2-p53 pathway by the IGF-1/AKT signaling cascade. AKT has been previously shown to physically interact with and phosphorylate MDM2, which facilitates MDM2 nuclear translocation . Phosphorylation of MDM2 enhances MDM2’s interaction with p300, thus increasing ubiquitin E3 ligase activity toward p53 and facilitating p53 ubiquitination and degradation . In addition, phosphorylation of MDM2 on Ser166 and Ser188 by AKT has been shown to stabilize MDM2 protein by inhibiting its self-ubiquitination . However, it was also reported that AKT-mediated phosphorylation of MDM2 does not seem to dramatically affect MDM2 subcellular localization . Thus, although it is clear that AKT positively regulates MDM2, the precise molecular mechanisms seem to be cell type- and context-dependent.
Previous studies suggest that MDM2 can be regulated at the translational level. Enhanced translation of MDM2 has been observed in human choriocarcinoma cell lines . The MDM2 mRNA contains a distinct 5' untranslated region (UTR) that plays a role in translational efficiency . In addition, increased MDM2 expression induced by BCR/ABL expression is associated with enhanced MDM2 translation due to regulation at the 5′ UTR of MDM2 mRNA . Moreover, inhibition of IGF-1 signaling, either by knockout of IGF-1 receptor (IGF-1R) or by an IGF-1R kinase inhibitor, has been shown to decrease MDM2 translation mediated via its 5′ UTR . Notably, it has been reported that hepatocyte growth factor (HGF) facilitates MDM2 translation via mTOR in embryonic hepatocytes .
In this study, we show that both IGF-1 and heregulin signaling activate MDM2 through the AKT-mTOR pathway. This study has two important implications. First, cellular responses to a variety of stresses converge on the p53-MDM2 pathway, which serves as the central sensor for stress. Second, there are two major regulatory mechanisms to modulate MDM2 protein levels: p53-dependent transcriptional regulation and mTOR-dependent translational control. Stress signals, including DNA damage, hypoxia, nutrient deprivation and oxidative stress, activate p53, which in turn transcriptionally up-regulates MDM2 expression. Growth factor signaling, on the other hand, activates the AKT-mTOR pathway to enhance MDM2 protein translation. This delicate regulation of MDM2 ensures that p53 is under tight control. Moreover, our data show that eIF4E or S6K ablation do not significantly affect MDM2 basal levels. However, silencing of either eIF4E or S6K completely abolished IGF-1-induced MDM2 up-regulation. These results indicate that the mTOR pathway is required for growth factor-mediated MDM2 up-regulation.
Inhibition of mTOR using specific pharmacological inhibitors results in G1/S cell cycle arrest, attenuation of cell growth, and apoptosis . Pre-clinical studies indicate that rapamycin and its derivatives inhibit cancer cell growth and proliferation, which has been shown both in vitro and in a variety of human cancers using animal models . In addition, it was reported that inhibition of mTOR promotes apoptosis through translational control of Mcl-1, a bcl-2 like family member . However, in most cases, inhibition of mTOR alone does not effectively induce apoptosis; rather, it sensitizes cells to apoptotic stimuli. For instance, rapamycin increases the ability of cisplatin to induce apoptosis in human promyelocytic leukemia cell lines and ovarian cancer cell lines . RAD001, a rapamycin derivative, has been shown to sensitize a number of p53-positive cancer cells to cisplatin-induced apoptosis by inhibiting p21 protein expression through the repression of general translation . Moreover, rapamycin sensitized multiple myeloma cell lines to dexamethasone-induced apoptosis, associated with decreased expression of cyclin D2 and survivin . It has also been reported that expression of constitutively active mutant 4E-BP1 mimics the effect of rapamycin in enhancing apoptosis in multiple myeloma cells, suggesting that the mTOR inhibitors sensitize cells by inhibiting cap-dependent translation . Consistent with this notion, small molecules that target cap-dependent translation initiation by inhibition of eIF4A can restore drug sensitivity in a mouse lymphoma model .
In this study, we observed that rapamycin and doxorubicin combination treatment led to reduced MDM2 expression, which resulted in increased apoptosis, implicating that p53 may be involved in this process. Our data showed that doxorubicin up-regulated p53, as expected. However, while rapamycin/doxorubicin combination treatment did not significantly affect p53 protein levels, phosphorylation at serine 15 on p53 were increased, suggesting that p53 activity was induced. Importantly, ectopic expression of MDM2 reversed apoptosis, concomitant with reduced p53 protein levels and serine 15 phosphorylation. Nonetheless, MDM2 may also have p53-independent functions to inhibit apoptosis in the presence of doxorubicin/rapamycin combination treatment.
In summary, our study shows that rapamycin sensitizes cancer cells to chemotherapeutic drug-induced apoptosis and suggests that mTOR-targeted anticancer-therapy combined with chemotherapy may be more effective in treatment of p53-positive cancers.
Human breast carcinoma MCF-7 cells, osteosarcoma U2-OS cells and non-small cell lung carcinoma H1299 cells were maintained in Dulbecco’s modified Eagle medium (DMEM) containing 4.5 g/L glucose supplemented with 10% fetal bovine serum (FBS; certified, GIBCO), 100 units/mL penicillin (GIBCO), 100 µg/mL streptomycin (GIBCO), and 2 mM L-Glutamine (GIBCO). All cell lines were passaged using 0.05% Trypsin-EDTA solution (GIBCO). Cells were maintained in a humidified 37°C incubator under a 5% CO2 atmosphere. Cells were obtained from American Type Culture Collection (ATCC). MCF-7, U2-OS or H1299 cells at 60–70% confluence were serum starved for 24 hours in serum-free DMEM prior to IGF-1 treatment. IGF-1 (Sigma) was prepared as a 100 µg/mL stock solution in water. Chemical inhibitors LY294002, PD98059, SB202190 (Calbiochem), and Rapamycin (Sigma) were prepared as 1,000× stock solutions. Doxorubicin (Sigma) was prepared as a 2 mg/mL stock solution. Heregulin-beta (Upstate) was prepared as a 20 µg/mL solution in PBS. For UV treatment, media were removed and the cells irradiated with lids removed in a Spectrolinker XL-1000 UV Crosslinker (Spectronics Corporation). After irradiation, media were added to the dishes and the cells were grown as indicated for each experiment before collection of both floating and adherent cells.
Cells at 60% confluence were infected with Adenovirus encoding AKT or a vector control, and incubated for two hours at 37°C with mild agitation at twenty-minute intervals, followed by the addition of culture media and incubated at 37°C with 5% CO2 for 24 hours. H1299 cells at 80% confluency or U2-OS cells at 50% confluency were transfected using Lipofectamine 2000 transfection reagent (Invitrogen), according to manufacturer’s instructions. Media were replaced eight (H1299) or six (U2-OS) hours after transfection. Small interfering RNA against eIF4E (AAGCAAACCUGCGGCUGAUCU), S6K (GGACATGGCAGGAGTGTTT) and scrambled siRNA controls specific for each siRNA oligonucleotide were purchased from Shanghai GenePharma Co., Ltd. and transfected using Lipofectamine 2000 (Invitrogen).
Cells were collected, washed with PBS, and resuspended in EBC250 lysis buffer (250 mM NaCl, 50 mM Tris pH 8.0, 0.5% Nonidet P-40, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride, 2 µg/mL aprotinin, and 2 µg/mL leupeptin). Protein concentration was determined using the Bio-Rad Protein Assay Reagent (Bio-Rad). Equal amounts of protein were loaded, separated by SDS-PAGE, transferred to PVDF membranes (Millipore), and hybridized to an appropriate primary antibody and HRP-conjugated secondary antibody for subsequent detection by enhanced chemiluminescence. Monoclonal antibody SMP14 specific for MDM2 (Santa Cruz) was used at 1200 dilutions. Monoclonal antibody DO-1 specific for p53 (Santa Cruz) was used at a dilution of 1250. Polyclonal antibody C-11 specific for actin (Santa Cruz) was used at a dilution of 11000. Antibodies specific for PARP (#9542), phospho-AKT (Ser473; #9271), total AKT (#9272), Phospho-S6 Ribosomal Protein (serine 235/236; #2211), S6 Ribosomal Protein (#2217), S6 Kinase (#9202), eIF4E, Phospho-4EBP1 (Ser65; #9456) or 4EBP1 (#9452) were purchased from Cell Signaling Technology and used at 11000 dilutions.
Cells were trypsinized, washed with cold PBS, and fixed in 70% ethanol at 4°C overnight. Cells were stained with propidium iodide (PI) supplemented with 80 µg/mL RNase A at 37°C in dark for one hour. Cells were then subjected to flow cytometry analysis by FACScan Flow Cytometer (Becton Dickson), and the data were analyzed using Cell Quest software (Becton Dickson).
Total RNA was extracted from cells using Tryzol according to manufacturer’s instructions (Gibco). RNA was reverse transcribed using iScript cDNA Synthesis Kit (BioRad). The reaction was also carried out in the absence of reverse transcriptase to serve as a negative control. Q-PCR was carried out in 25 µL reaction volumes (8 ng cDNA, 12.5 µL Taqman Universal PCR Master Mix, 1.25 µL Demand Gene Expression Reagent; Applied Biosystems) for both MDM2 and GAPDH. The Q-PCR reaction was performed in an ABI Prism 7000 Sequence detection System (Applied Biosystems). The Q-PCR conditions were as follows: 10 minutes at 95°C followed by 40 cycles of denaturing at 95°C for 15 seconds and annealing/extending at 60°C for one minute. Relative quantitation values were calculated using the ΔΔCt method.
Both floating and adherent cells were collected and resuspended in PBS. Equal volumes of trypan blue stain solution (0.4%; Gibco) and cell suspension were mixed and stained for five minutes at room temperature. The numbers of stained and unstained cells were counted with a hemacytometer. At least 500 cells per sample were counted. The percentage of viability represents the ratio of unstained cells to total cells. Student’s t-test was used to determine statistical significance of differences between groups.
We thank Dr. J Lawrence (University of Virginia, Charlottesville, Virginia) for pCMV4-4EBP1 and pCMV4-4EBP1-5A plasmids.